Artivion (AORT)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-09
$25.22+0.36%
Close 2026-09-09 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Revenue grows to at least $488 million in FY26: FY26 rev guide $480M-$496M vs $488M target.
Artivion grew revenue 18% year over year to $116 million in Q1 2026. Operating income improved to $5.8 million from $2.1 million a year ago. The company completed the Endospan acquisition to expand its aortic arch products. Management is on track to increase revenue and improve profits.
The company recently cut full-year revenue guidance to about $488 million. Earnings estimates have been revised down in the last 30 days. The stock is under pressure from a 37% drawdown and a recent selloff. Growth may slow and margins could weaken.
The stock trades about 4% above our fair value near $23. Analysts expect roughly 12% revenue growth. Our view aligns with consensus but notes risks from lowered guidance and estimate cuts.
Breaks if: Integration progress score falls below 50%
Finalize and integrate the acquisition of Endospan Ltd. to expand Artivion's aortic arch product portfolio and pipeline.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state is intact, supported by recent strong financial performance and management's focus on revenue growth and operating income improvement.
The market seems to have priced in a low level of execution quality, reflecting some fragility in the business. AORT's valuation indicates a durable premium compared to peers, suggesting that the expectations are somewhat justified but with a slight gap.
Fundamentals are likely to show continued revenue growth, as management has delivered consistent results aligned with guidance. However, there is a risk of missing expectations due to the company's recent history of earnings misses.
The thesis hinges on management's ability to maintain revenue growth and improve operating income while navigating potential risks from macroeconomic factors. Key triggers include guidance cuts or sector performance from major healthcare companies.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 disclosures including 2026-Q1 and 2026-Q2. The acquisition closed in May 2026 with a $135 million upfront payment funded by a $150 million loan. Management has delivered this milestone ahead of initial expectations, fulfilling the stated priority.
“We completed the acquisition of Endospan Ltd. sooner than anticipated; NEXUS completes our aortic arch portfolio.”
“We exercised our option to acquire Endospan and expect the acquisition to close in Q2 2026.”
Breaks if: Operating income falls below $5 million per quarter
Enhance operating income through revenue growth and expense management, targeting adjusted EBITDA growth in 2026.
Management emphasized improving operating income in 4 quarters including 2025-Q4 through 2026-Q2. Adjusted EBITDA grew from $24.8 million in Q2 2025 to $26.4 million in Q2 2026 (7% growth). Full year 2026 adjusted EBITDA guidance of $92 to $99 million reflects continued growth but slightly below earlier guidance, indicating delivering with some moderation.
“Adjusted EBITDA increased 7% to $26.4 million in Q2 2026 compared to Q2 2025.”
“Adjusted EBITDA increased 26% to $22.1 million in Q1 2026 compared to Q1 2025.”
“Adjusted EBITDA increased 29% to $22.7 million in Q4 2025 compared to Q4 2024.”
“Adjusted EBITDA increased 26% for full year 2025 to $89.6 million.”
Breaks if: Revenue falls below $480 million in FY26
Over the next 1 to 3 years, AORT's performance will depend on its ability to execute on growth strategies amidst elevated risks. Not investment advice.